Parp Inhibitor Biomarkers Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook 2026-2030

PARP inhibitor biomarkers are molecular indicators, most notably BRCA1, BRCA2, and homologous recombination deficiency (HRD) status, used to identify cancer patients most likely to respond to PARP inhibitor drugs. Testing products include molecular diagnostic kits, next-generation sequencing instruments, and companion diagnostic panels supplied to clinical laboratories and hospitals. The market is structurally supported by FDA-approved PARP inhibitors such as olaparib, rucaparib, niraparib, and talazoparib, all of which require biomarker-guided patient selection.

• •Market valued at approximately $1.0 billion globally in 2025
• •Projected CAGR of approximately 9.5% through 2031-2035 across most industry forecasts
• •Segmented by product into kits/assays and instruments, and by biomarker into BRCA1/2, HRD, and other genomic indicators
• •Service-based testing and centralized laboratory models are a growing sub-segment

Rising global incidence of BRCA-associated cancers and an aging population are expanding the addressable patient pool for biomarker testing. Regulatory approvals of new PARP inhibitors across additional cancer types, including prostate, pancreatic, and breast cancers, are increasing the volume of companion diagnostic tests required. Growing adoption of personalized and precision oncology by healthcare providers and payers further accelerates demand for validated biomarker assays.

• •Increasing prevalence of hereditary breast, ovarian, prostate, and pancreatic cancers linked to BRCA mutations
• •Expanding label indications for PARP inhibitors driving higher companion diagnostic test volumes
• •Government and insurer support for precision oncology programs reducing reimbursement barriers

By product, the market is divided into kits and reagents (the dominant segment), diagnostic instruments, and outsourced laboratory services. By biomarker, BRCA1/2 testing remains the largest category, though HRD and multi-gene panel tests are gaining share. Geographically, North America holds the largest market share due to advanced oncology infrastructure, high drug utilization, and favorable reimbursement policies. Europe and the Asia-Pacific region follow, with the Asia-Pacific market expected to grow at the fastest rate as cancer screening and genomic medicine capacity expand.

• •North America leads the market, supported by early drug adoption, established companion diagnostic frameworks, and comprehensive insurance coverage
• •Europe represents a strong second market driven by centralized healthcare systems and widespread genomic testing programs
• •Asia-Pacific is the fastest-growing region, fueled by rising cancer incidence, expanding healthcare access, and growing investment in precision medicine

What are the recent trends and outlook?

Advances in next-generation sequencing and liquid biopsy technologies are making PARP biomarker testing faster, less invasive, and more accessible outside major academic centers. Multiplex biomarker panels that assess HRD and additional homologous recombination genes alongside BRCA are expected to broaden the addressable patient population and improve clinical outcomes. As competition among PARP inhibitors intensifies, biomarker-driven stratification will remain central to clinical development and market differentiation through the forecast period.

• •Integration of next-generation sequencing and liquid biopsy is enabling earlier detection and less invasive monitoring of BRCA and HRD biomarkers
• •Multi-gene and HRD scoring panels are emerging to capture a broader range of PARP inhibitor-responsive patients
• •The market is expected to reach approximately $2.0-$2.5 billion by the early 2030s, underpinned by new drug approvals and expanding global access to genomic testing